Nebivolol Sandoz (Nebivolol Hydrochloride)

Nebivolol is a selective β1‑adrenergic receptor blocker used in cardiovascular therapy.

• Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
• Heart failure: improves cardiac function and reduces symptoms in chronic heart failure.
• Left ventricular systolic dysfunction: enhances ejection fraction in patients with reduced left ventricular function.

• Nebivolol selectively antagonizes β1‑adrenergic receptors on cardiac tissue, reducing heart rate and myocardial contractility. Concurrently, it stimulates endothelial nitric‑oxide synthase, leading to nitric‑oxide release and vasodilation. This dual action decreases peripheral vascular resistance and arterial pressure while improving cardiac output, making it effective for managing hypertension and certain forms of heart failure.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Headache: mild to moderate headache reported.
• Dizziness: sensation of light‑headedness, especially on standing.
• Fatigue: general tiredness or lack of energy.
• Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Hypotension: significant drop in blood pressure that may cause fainting.
• Bronchospasm: narrowing of airways, particularly in patients with asthma or COPD.
• Cardiac conduction abnormalities: such as AV block or heart block.
• Allergic reactions: rash, itching, or swelling indicating hypersensitivity.

Before prescribing Nebivolol, clinicians should consider several safety factors.

• Cardiovascular assessment: evaluate baseline heart rate and blood pressure.
• Renal impairment: monitor renal function and adjust therapy if needed.
• Hepatic impairment: use with caution in patients with liver disease.
• Concomitant β‑blockers: avoid additive bradycardic effects.
• Pregnancy and lactation: use only if potential benefits justify potential risks.
• Store at ambient temperature: keep below 25°C, protect from moisture and light.

Nebivolol can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Non‑selective β‑blockers: may cause excessive bradycardia.
• Calcium channel blockers (verapamil, diltiazem): increase risk of AV block.
• Clonidine: abrupt discontinuation may lead to rebound hypertension.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may enhance hypotensive effect.
• Diuretics: increase risk of electrolyte disturbances.
• Antidiabetic drugs: may mask symptoms of hypoglycemia.